Royalty PharmaRPRX.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Richly Valued” zone.
As of Oct 16, 2026, Royalty Pharma (RPRX.O) trades at a P/E of 43.00x, P/B of 5.10x, P/S of 13.80x, and a dividend yield of 1.16%.
Longitudinal percentile comparison: P/E sits at the 75th percentile over the trailing 10Y window (vs. 92nd percentile over 3Y); P/B sits at the 84th percentile over the trailing 10Y window (vs. 99th percentile over 3Y); P/S sits at the 97th percentile over the trailing 10Y window (vs. 99th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 78th percentile within its industry and the 81st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 4.66%, ranking at the 88th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 9.5 points of each other — a consistent signal from both angles. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 4.66% total shareholder yield, 1.16% is paid out as dividends and roughly 3.50% is implied to come from buybacks — both channels are meaningfully in play. Royalty Pharma operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: RPRX · RPRX
Want the full picture on whether Royalty Pharma (RPRX.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 43.00 | ||||||
| P/B (MRQ) | 5.10 | ||||||
| P/S (TTM) | 13.80 | ||||||
| Dividend Yield | 1.16% | ||||||
| Buyback + Div Yield | 4.66% |